Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus

Type 2 Diabetes Clinical Trial

— TK-SEEK  

Official title:

Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus (TK-SEEK): a Prospective, Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06085378
• Other study ID #: IIT-2023-509
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2024
• Est. completion date: December 31, 2026

Study information

• Verified date: October 2023
• Source: First Affiliated Hospital, Sun Yat-Sen University
• Contact: Jinsheng Zeng
• Phone: +8613322800657
• Email: zengjs[@]pub.guangzhou.gd.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multicenter, randomized, double-blind, placebo parallel control study, aim to evaluate the efficacy and safety of human urinary kallidinogenase in the treatment of acute ischemic stroke with type 2 diabetes.

Description:

The study process lasts for a total of 90 days, including the screening period, intervention period, and follow-up period. During the intervention period, the experimental group is treated with Urinary Kallidinogenase, while the control group is treated with placebo for 10 days. Both groups receive routine clinical treatment. All patients are followed up until the 90th day after stroke. The sample size of the study is 630 patients. The ratio of the experimental group to the control group is 1:1.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 630
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age =18 years old and =80 years old;
• Patients with acute ischemic stroke diagnosed with complete anterior circulation infarction (TACI) and partial anterior circulation infarction (PACI) according to Oxfordshire Community Stroke Project classification (OCSP), see Appendix 6;
• Refer to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition), have been diagnosed with type 2 diabetes (need to have a medical history to confirm), see Appendix 7;
• The time from the occurrence of the stroke to the time of admission is less than 48h. If the exact time of onset is unknown, the time of onset of the patient is defined as "the time that finally seems normal";
• First-ever ischemic stroke or have history of ischemic stroke but mRS=1 before onset;
• 6=NIHSS=20;
• Have provided signed written informed consent from the patient or the patient's legal representative

Exclusion Criteria:

• Acute intracranial hemorrhagic diseases confirmed by imaging: parenchymal hemorrhage, epidural hematoma, subdural hematoma, ventricle hemorrhage, subarachnoid hemorrhage, etc.
• Patients who are ready to undergo or have undergone intravascular interventional therapy after the onset of the disease;
• Patients who are ready to undergo or have undergone intravenous thrombolytic therapy after the onset of the disease;
• Severe disturbance of consciousness: NIHSS 1a consciousness level score =2;
• Patients with fracture, claudication and other factors affecting functional outcome score upon admission;
• After the onset of the disease, Edaravone injection, Edaravone and Dexborneol concentrated solution for injection, Butylphthalide and sodium chloride injection or Butylphthalide soft capsules have been used;
• Chinese patent medicine injection for improving cerebral blood circulation has been applied after the onset of this disease (see 8.4.2 for details);
• Patients with hypotension (blood pressure less than 90/60mmHg) upon admission;
• Have a history of severe food or drug allergy, or have been allergic to or intolerant of Eurecline injection;
• Eurecline for injection has used angiotensin-converting enzyme inhibitor (ACEI) drugs before taking the drug and has not exceeded 5 half-lives (according to the specific drug instructions);
• Patients who are pregnant or breastfeeding and who plan to become pregnant within 90 days;
• Renal failure or severe renal impairment at the time of screening (creatinine clearance < 30ml/min);
• Liver function impairment: alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 2.5 times the upper limit of normal, or other known serious liver diseases such as active infection of acute and chronic hepatitis, cirrhosis, etc.;
• Patients with heart failure (NYHA class III or IV), unstable angina pectoris, acute myocardial infarction, severe arrhythmia, and degree II and III cardiac conduction obstruction within 6 months prior to randomization;
• Those who meet the heavy drinking standard in the three months before the screening period, that is, drinking =5 standard drinks per day (1 standard drink is equivalent to 120ml wine, 360ml beer or 45ml liquor);
• Patients who have abused or become addicted to drugs (narcotics, drugs) in the past year;
• Patients with malignant tumors or severe systemic diseases with an expected survival of less than 90 days;
• Patients with serious mental disorders or dementia who cannot cooperate to complete informed consent and follow-up;
• Participated in any interventional drug or device clinical trials within 3 months prior to screening;
• Patients deemed unsuitable for study participation by the investigator;

Related Conditions & MeSH terms

• Acute Ischemic Stroke
• Cerebral Infarction
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Ischemia
• Ischemic Stroke
• Stroke
• Type 2 Diabetes

Intervention

Drug:
• Urinary Kallidinogenase for injection
The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days

Other:
• Placebo
The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.

Locations

Country	Name	City	State
China	The First Affiliated Hospital, Sun Yat-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes of fasting blood glucose values from baseline to 10 days	Changes of fasting blood glucose values from baseline to 10 days	from baseline to day 10
Other	Changes of HBA1c from baseline to 90±7 days	Changes of HBA1c from baseline to 90±7 days	from baseline to day 90±7
Other	Changes of hypersensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6)	Changes of hypersensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6)	from baseline to day 10
Other	Changes of urea nitrogen, creatinine and urinary protein	Changes of urea nitrogen, creatinine and urinary protein	from baseline to day 10
Other	Stroke recurrence rate within 90 days	Stroke recurrence rate within 90 days	90 days
Other	Incidence, severity, and causality of adverse events (AE) and serious adverse events (SAE) during the intervention	Incidence, severity, and causality of adverse events (AE) and serious adverse events (SAE) during the intervention	during the intervention
Primary	The proportion of patients with modified rankin scale (mRS) 0-2 scores at 90±7 days	The proportion of patients with modified rankin scale (mRS) 0-2 scores at 90±7 days	90±7 days
Secondary	The proportion of patients with modified rankin scale (mRS) 0-3 scores at 90±7 days	The proportion of patients with modified rankin scale (mRS) 0-3 scores at 90±7 days	90±7 days
Secondary	Distribution of modified rankin scale (mRS) at 90±7 days	Distribution of modified rankin scale (mRS) at 90±7 days	90±7 days
Secondary	Changes of NIHSS from baseline to 10 days	Changes of NIHSS from baseline to 10 days	from baseline to day 10
Secondary	Changes of Barthel index from baseline to 90±7 days	Changes of Barthel index from baseline to 90±7 days	from baseline to day 90±7
Secondary	Changes of mini-mental state examination (MMSE) from baseline to 90±7 days	Changes of mini-mental state examination (MMSE) from baseline to 90±7 days	from baseline to day 90±7
Secondary	Changes of Montreal cognitive assessment (MoCA) from baseline to 90±7 days	Changes of Montreal cognitive assessment (MoCA) from baseline to 90±7 days	from baseline to day 90±7